nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—colon cancer—Dexamethasone—hematologic cancer	0.161	0.366	CpDpCtD
Aprepitant—colon cancer—Betamethasone—hematologic cancer	0.161	0.366	CpDpCtD
Aprepitant—breast cancer—Betamethasone—hematologic cancer	0.059	0.134	CpDpCtD
Aprepitant—breast cancer—Dexamethasone—hematologic cancer	0.059	0.134	CpDpCtD
Aprepitant—CYP1A2—Anagrelide—hematologic cancer	0.0159	0.0451	CbGbCtD
Aprepitant—CYP2C9—Bexarotene—hematologic cancer	0.00994	0.0282	CbGbCtD
Aprepitant—CYP3A7—Ifosfamide—hematologic cancer	0.00929	0.0263	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.00929	0.0263	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.00888	0.0251	CbGbCtD
Aprepitant—CYP3A7—Imatinib—hematologic cancer	0.00888	0.0251	CbGbCtD
Aprepitant—CYP3A5—Daunorubicin—hematologic cancer	0.00869	0.0246	CbGbCtD
Aprepitant—CYP1A2—Carmustine—hematologic cancer	0.00836	0.0237	CbGbCtD
Aprepitant—CYP2C9—Idarubicin—hematologic cancer	0.00824	0.0233	CbGbCtD
Aprepitant—CYP3A5—Thalidomide—hematologic cancer	0.00792	0.0224	CbGbCtD
Aprepitant—CYP3A5—Teniposide—hematologic cancer	0.00755	0.0214	CbGbCtD
Aprepitant—CYP2C19—Bortezomib—hematologic cancer	0.00733	0.0208	CbGbCtD
Aprepitant—CYP1A2—Methoxsalen—hematologic cancer	0.00711	0.0201	CbGbCtD
Aprepitant—CYP3A5—Ifosfamide—hematologic cancer	0.00697	0.0197	CbGbCtD
Aprepitant—CYP1A2—Bortezomib—hematologic cancer	0.00676	0.0192	CbGbCtD
Aprepitant—CYP3A5—Imatinib—hematologic cancer	0.00666	0.0189	CbGbCtD
Aprepitant—CYP1A2—Daunorubicin—hematologic cancer	0.00647	0.0183	CbGbCtD
Aprepitant—CYP2C19—Thalidomide—hematologic cancer	0.00639	0.0181	CbGbCtD
Aprepitant—CYP1A2—Alitretinoin—hematologic cancer	0.00634	0.018	CbGbCtD
Aprepitant—CYP2C9—Bortezomib—hematologic cancer	0.0061	0.0173	CbGbCtD
Aprepitant—CYP2C19—Teniposide—hematologic cancer	0.00609	0.0173	CbGbCtD
Aprepitant—CYP1A2—Thalidomide—hematologic cancer	0.00589	0.0167	CbGbCtD
Aprepitant—CYP3A4—Bexarotene—hematologic cancer	0.00578	0.0164	CbGbCtD
Aprepitant—CYP2C19—Ifosfamide—hematologic cancer	0.00562	0.0159	CbGbCtD
Aprepitant—CYP3A7—Irinotecan—hematologic cancer	0.00554	0.0157	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.00554	0.0157	CbGbCtD
Aprepitant—CYP3A4—Lomustine—hematologic cancer	0.00538	0.0152	CbGbCtD
Aprepitant—CYP3A4—Busulfan—hematologic cancer	0.00538	0.0152	CbGbCtD
Aprepitant—CYP2C19—Imatinib—hematologic cancer	0.00537	0.0152	CbGbCtD
Aprepitant—CYP3A5—Dasatinib—hematologic cancer	0.00535	0.0151	CbGbCtD
Aprepitant—CYP2C9—Thalidomide—hematologic cancer	0.00531	0.015	CbGbCtD
Aprepitant—CYP1A2—Dacarbazine—hematologic cancer	0.00507	0.0144	CbGbCtD
Aprepitant—CYP2C9—Teniposide—hematologic cancer	0.00507	0.0143	CbGbCtD
Aprepitant—CYP1A2—Imatinib—hematologic cancer	0.00496	0.014	CbGbCtD
Aprepitant—CYP3A7—Vincristine—hematologic cancer	0.00485	0.0137	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.00485	0.0137	CbGbCtD
Aprepitant—CYP3A4—Thiotepa—hematologic cancer	0.00479	0.0136	CbGbCtD
Aprepitant—CYP2C9—Ifosfamide—hematologic cancer	0.00467	0.0132	CbGbCtD
Aprepitant—CYP2C9—Imatinib—hematologic cancer	0.00447	0.0126	CbGbCtD
Aprepitant—CYP3A5—Irinotecan—hematologic cancer	0.00416	0.0118	CbGbCtD
Aprepitant—CYP2C9—Nilotinib—hematologic cancer	0.00406	0.0115	CbGbCtD
Aprepitant—CYP1A2—Dasatinib—hematologic cancer	0.00398	0.0113	CbGbCtD
Aprepitant—CYP3A4—Methoxsalen—hematologic cancer	0.00373	0.0106	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00365	0.0103	CbGbCtD
Aprepitant—CYP3A7—Dexamethasone—hematologic cancer	0.00365	0.0103	CbGbCtD
Aprepitant—CYP3A5—Vincristine—hematologic cancer	0.00364	0.0103	CbGbCtD
Aprepitant—CYP3A4—Bortezomib—hematologic cancer	0.00354	0.01	CbGbCtD
Aprepitant—CYP2C19—Prednisone—hematologic cancer	0.00354	0.01	CbGbCtD
Aprepitant—CYP3A4—Daunorubicin—hematologic cancer	0.00339	0.0096	CbGbCtD
Aprepitant—CYP3A5—Etoposide—hematologic cancer	0.00333	0.00943	CbGbCtD
Aprepitant—CYP3A4—Cytarabine—hematologic cancer	0.00299	0.00847	CbGbCtD
Aprepitant—CYP3A4—Teniposide—hematologic cancer	0.00295	0.00834	CbGbCtD
Aprepitant—CYP3A5—Dexamethasone—hematologic cancer	0.00274	0.00776	CbGbCtD
Aprepitant—CYP3A4—Ifosfamide—hematologic cancer	0.00272	0.0077	CbGbCtD
Aprepitant—CYP3A4—Imatinib—hematologic cancer	0.0026	0.00735	CbGbCtD
Aprepitant—CYP1A2—Etoposide—hematologic cancer	0.00248	0.00702	CbGbCtD
Aprepitant—CYP3A4—Ruxolitinib—hematologic cancer	0.00245	0.00692	CbGbCtD
Aprepitant—CYP3A4—Nilotinib—hematologic cancer	0.00236	0.00668	CbGbCtD
Aprepitant—CYP3A4—Vinorelbine—hematologic cancer	0.00234	0.00663	CbGbCtD
Aprepitant—CYP2C9—Cisplatin—hematologic cancer	0.00227	0.00644	CbGbCtD
Aprepitant—CYP2C19—Dexamethasone—hematologic cancer	0.00221	0.00626	CbGbCtD
Aprepitant—CYP3A4—Triamcinolone—hematologic cancer	0.00214	0.00606	CbGbCtD
Aprepitant—CYP3A4—Dasatinib—hematologic cancer	0.00209	0.00591	CbGbCtD
Aprepitant—CYP3A4—Mitoxantrone—hematologic cancer	0.00206	0.00583	CbGbCtD
Aprepitant—CYP2C9—Dexamethasone—hematologic cancer	0.00184	0.0052	CbGbCtD
Aprepitant—CYP3A4—Betamethasone—hematologic cancer	0.00184	0.0052	CbGbCtD
Aprepitant—CYP3A4—Prednisolone—hematologic cancer	0.00181	0.00513	CbGbCtD
Aprepitant—CYP3A4—Prednisone—hematologic cancer	0.00171	0.00485	CbGbCtD
Aprepitant—CYP3A4—Irinotecan—hematologic cancer	0.00162	0.00459	CbGbCtD
Aprepitant—CYP3A4—Vinblastine—hematologic cancer	0.00144	0.00408	CbGbCtD
Aprepitant—CYP3A4—Vincristine—hematologic cancer	0.00142	0.00401	CbGbCtD
Aprepitant—CYP3A4—Etoposide—hematologic cancer	0.0013	0.00368	CbGbCtD
Aprepitant—CYP3A4—Dexamethasone—hematologic cancer	0.00107	0.00302	CbGbCtD
Aprepitant—CYP3A4—Doxorubicin—hematologic cancer	0.000886	0.00251	CbGbCtD
Aprepitant—TACR1—hematopoietic system—hematologic cancer	0.000464	0.165	CbGeAlD
Aprepitant—TACR1—blood—hematologic cancer	0.000308	0.109	CbGeAlD
Aprepitant—TACR1—lung—hematologic cancer	0.00027	0.0958	CbGeAlD
Aprepitant—TACR1—testis—hematologic cancer	0.000254	0.0904	CbGeAlD
Aprepitant—TACR1—lymph node—hematologic cancer	0.000184	0.0655	CbGeAlD
Aprepitant—CYP2C19—hematopoietic system—hematologic cancer	0.000177	0.063	CbGeAlD
Aprepitant—CYP1A2—hematopoietic system—hematologic cancer	0.000145	0.0514	CbGeAlD
Aprepitant—CYP3A5—hematopoietic system—hematologic cancer	0.00014	0.0496	CbGeAlD
Aprepitant—CYP2C9—hematopoietic system—hematologic cancer	0.000137	0.0488	CbGeAlD
Aprepitant—CYP2C19—blood—hematologic cancer	0.000117	0.0417	CbGeAlD
Aprepitant—CYP3A4—hematopoietic system—hematologic cancer	0.000105	0.0372	CbGeAlD
Aprepitant—CYP1A2—blood—hematologic cancer	9.59e-05	0.0341	CbGeAlD
Aprepitant—CYP3A5—blood—hematologic cancer	9.25e-05	0.0329	CbGeAlD
Aprepitant—CYP2C9—blood—hematologic cancer	9.11e-05	0.0323	CbGeAlD
Aprepitant—CYP1A2—lung—hematologic cancer	8.41e-05	0.0299	CbGeAlD
Aprepitant—CYP3A5—lung—hematologic cancer	8.11e-05	0.0288	CbGeAlD
Aprepitant—CYP3A4—blood—hematologic cancer	6.94e-05	0.0247	CbGeAlD
Aprepitant—Erythema multiforme—Doxorubicin—hematologic cancer	1.1e-05	6.8e-05	CcSEcCtD
Aprepitant—Rash—Cisplatin—hematologic cancer	1.1e-05	6.78e-05	CcSEcCtD
Aprepitant—Dermatitis—Cisplatin—hematologic cancer	1.1e-05	6.77e-05	CcSEcCtD
Aprepitant—Erythema—Epirubicin—hematologic cancer	1.09e-05	6.76e-05	CcSEcCtD
Aprepitant—Malnutrition—Epirubicin—hematologic cancer	1.09e-05	6.76e-05	CcSEcCtD
Aprepitant—Diarrhoea—Etoposide—hematologic cancer	1.09e-05	6.74e-05	CcSEcCtD
Aprepitant—Anorexia—Prednisone—hematologic cancer	1.09e-05	6.73e-05	CcSEcCtD
Aprepitant—Eye disorder—Doxorubicin—hematologic cancer	1.09e-05	6.72e-05	CcSEcCtD
Aprepitant—Ill-defined disorder—Methotrexate—hematologic cancer	1.09e-05	6.71e-05	CcSEcCtD
Aprepitant—Tinnitus—Doxorubicin—hematologic cancer	1.09e-05	6.7e-05	CcSEcCtD
Aprepitant—Anaemia—Methotrexate—hematologic cancer	1.08e-05	6.68e-05	CcSEcCtD
Aprepitant—Feeling abnormal—Dexamethasone—hematologic cancer	1.08e-05	6.68e-05	CcSEcCtD
Aprepitant—Feeling abnormal—Betamethasone—hematologic cancer	1.08e-05	6.68e-05	CcSEcCtD
Aprepitant—Flushing—Doxorubicin—hematologic cancer	1.08e-05	6.67e-05	CcSEcCtD
Aprepitant—Cardiac disorder—Doxorubicin—hematologic cancer	1.08e-05	6.67e-05	CcSEcCtD
Aprepitant—Flatulence—Epirubicin—hematologic cancer	1.08e-05	6.67e-05	CcSEcCtD
Aprepitant—Gastrointestinal pain—Betamethasone—hematologic cancer	1.07e-05	6.63e-05	CcSEcCtD
Aprepitant—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.07e-05	6.63e-05	CcSEcCtD
Aprepitant—Dysgeusia—Epirubicin—hematologic cancer	1.07e-05	6.62e-05	CcSEcCtD
Aprepitant—Hypersensitivity—Triamcinolone—hematologic cancer	1.07e-05	6.58e-05	CcSEcCtD
Aprepitant—Back pain—Epirubicin—hematologic cancer	1.06e-05	6.54e-05	CcSEcCtD
Aprepitant—Angiopathy—Doxorubicin—hematologic cancer	1.06e-05	6.52e-05	CcSEcCtD
Aprepitant—Malaise—Methotrexate—hematologic cancer	1.06e-05	6.52e-05	CcSEcCtD
Aprepitant—Dizziness—Etoposide—hematologic cancer	1.05e-05	6.51e-05	CcSEcCtD
Aprepitant—Muscle spasms—Epirubicin—hematologic cancer	1.05e-05	6.5e-05	CcSEcCtD
Aprepitant—Immune system disorder—Doxorubicin—hematologic cancer	1.05e-05	6.49e-05	CcSEcCtD
Aprepitant—Mediastinal disorder—Doxorubicin—hematologic cancer	1.05e-05	6.48e-05	CcSEcCtD
Aprepitant—Chills—Doxorubicin—hematologic cancer	1.04e-05	6.45e-05	CcSEcCtD
Aprepitant—Urticaria—Dexamethasone—hematologic cancer	1.04e-05	6.44e-05	CcSEcCtD
Aprepitant—Urticaria—Betamethasone—hematologic cancer	1.04e-05	6.44e-05	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.04e-05	6.43e-05	CcSEcCtD
Aprepitant—Dizziness—Prednisolone—hematologic cancer	1.04e-05	6.42e-05	CcSEcCtD
Aprepitant—Asthenia—Triamcinolone—hematologic cancer	1.04e-05	6.41e-05	CcSEcCtD
Aprepitant—Body temperature increased—Dexamethasone—hematologic cancer	1.04e-05	6.41e-05	CcSEcCtD
Aprepitant—Abdominal pain—Dexamethasone—hematologic cancer	1.04e-05	6.41e-05	CcSEcCtD
Aprepitant—Abdominal pain—Betamethasone—hematologic cancer	1.04e-05	6.41e-05	CcSEcCtD
Aprepitant—Body temperature increased—Betamethasone—hematologic cancer	1.04e-05	6.41e-05	CcSEcCtD
Aprepitant—Nausea—Cisplatin—hematologic cancer	1.03e-05	6.39e-05	CcSEcCtD
Aprepitant—Insomnia—Prednisone—hematologic cancer	1.03e-05	6.38e-05	CcSEcCtD
Aprepitant—Alopecia—Doxorubicin—hematologic cancer	1.03e-05	6.35e-05	CcSEcCtD
Aprepitant—Paraesthesia—Prednisone—hematologic cancer	1.03e-05	6.34e-05	CcSEcCtD
Aprepitant—Pruritus—Triamcinolone—hematologic cancer	1.02e-05	6.32e-05	CcSEcCtD
Aprepitant—Cough—Methotrexate—hematologic cancer	1.02e-05	6.31e-05	CcSEcCtD
Aprepitant—Mental disorder—Doxorubicin—hematologic cancer	1.02e-05	6.3e-05	CcSEcCtD
Aprepitant—Ill-defined disorder—Epirubicin—hematologic cancer	1.02e-05	6.28e-05	CcSEcCtD
Aprepitant—Convulsion—Methotrexate—hematologic cancer	1.01e-05	6.26e-05	CcSEcCtD
Aprepitant—Vomiting—Etoposide—hematologic cancer	1.01e-05	6.26e-05	CcSEcCtD
Aprepitant—Erythema—Doxorubicin—hematologic cancer	1.01e-05	6.26e-05	CcSEcCtD
Aprepitant—Malnutrition—Doxorubicin—hematologic cancer	1.01e-05	6.26e-05	CcSEcCtD
Aprepitant—Anaemia—Epirubicin—hematologic cancer	1.01e-05	6.25e-05	CcSEcCtD
Aprepitant—Dyspepsia—Prednisone—hematologic cancer	1.01e-05	6.21e-05	CcSEcCtD
Aprepitant—Rash—Etoposide—hematologic cancer	1.01e-05	6.21e-05	CcSEcCtD
Aprepitant—Dermatitis—Etoposide—hematologic cancer	1e-05	6.2e-05	CcSEcCtD
Aprepitant—Headache—Etoposide—hematologic cancer	9.99e-06	6.17e-05	CcSEcCtD
Aprepitant—Flatulence—Doxorubicin—hematologic cancer	9.98e-06	6.17e-05	CcSEcCtD
Aprepitant—Arthralgia—Methotrexate—hematologic cancer	9.96e-06	6.15e-05	CcSEcCtD
Aprepitant—Myalgia—Methotrexate—hematologic cancer	9.96e-06	6.15e-05	CcSEcCtD
Aprepitant—Chest pain—Methotrexate—hematologic cancer	9.96e-06	6.15e-05	CcSEcCtD
Aprepitant—Decreased appetite—Prednisone—hematologic cancer	9.93e-06	6.14e-05	CcSEcCtD
Aprepitant—Dysgeusia—Doxorubicin—hematologic cancer	9.92e-06	6.13e-05	CcSEcCtD
Aprepitant—Rash—Prednisolone—hematologic cancer	9.91e-06	6.12e-05	CcSEcCtD
Aprepitant—Dermatitis—Prednisolone—hematologic cancer	9.9e-06	6.12e-05	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	9.89e-06	6.11e-05	CcSEcCtD
Aprepitant—Malaise—Epirubicin—hematologic cancer	9.87e-06	6.1e-05	CcSEcCtD
Aprepitant—Fatigue—Prednisone—hematologic cancer	9.85e-06	6.09e-05	CcSEcCtD
Aprepitant—Headache—Prednisolone—hematologic cancer	9.85e-06	6.09e-05	CcSEcCtD
Aprepitant—Discomfort—Methotrexate—hematologic cancer	9.84e-06	6.08e-05	CcSEcCtD
Aprepitant—Syncope—Epirubicin—hematologic cancer	9.82e-06	6.07e-05	CcSEcCtD
Aprepitant—Back pain—Doxorubicin—hematologic cancer	9.8e-06	6.05e-05	CcSEcCtD
Aprepitant—Constipation—Prednisone—hematologic cancer	9.77e-06	6.04e-05	CcSEcCtD
Aprepitant—Muscle spasms—Doxorubicin—hematologic cancer	9.74e-06	6.02e-05	CcSEcCtD
Aprepitant—Palpitations—Epirubicin—hematologic cancer	9.68e-06	5.98e-05	CcSEcCtD
Aprepitant—Confusional state—Methotrexate—hematologic cancer	9.63e-06	5.95e-05	CcSEcCtD
Aprepitant—Loss of consciousness—Epirubicin—hematologic cancer	9.62e-06	5.95e-05	CcSEcCtD
Aprepitant—Dizziness—Triamcinolone—hematologic cancer	9.56e-06	5.91e-05	CcSEcCtD
Aprepitant—Cough—Epirubicin—hematologic cancer	9.55e-06	5.9e-05	CcSEcCtD
Aprepitant—Anaphylactic shock—Methotrexate—hematologic cancer	9.55e-06	5.9e-05	CcSEcCtD
Aprepitant—Convulsion—Epirubicin—hematologic cancer	9.49e-06	5.86e-05	CcSEcCtD
Aprepitant—Infection—Methotrexate—hematologic cancer	9.49e-06	5.86e-05	CcSEcCtD
Aprepitant—Nausea—Etoposide—hematologic cancer	9.47e-06	5.85e-05	CcSEcCtD
Aprepitant—Hypertension—Epirubicin—hematologic cancer	9.45e-06	5.84e-05	CcSEcCtD
Aprepitant—Feeling abnormal—Prednisone—hematologic cancer	9.42e-06	5.82e-05	CcSEcCtD
Aprepitant—Asthenia—Betamethasone—hematologic cancer	9.41e-06	5.82e-05	CcSEcCtD
Aprepitant—Asthenia—Dexamethasone—hematologic cancer	9.41e-06	5.82e-05	CcSEcCtD
Aprepitant—Ill-defined disorder—Doxorubicin—hematologic cancer	9.4e-06	5.81e-05	CcSEcCtD
Aprepitant—Nervous system disorder—Methotrexate—hematologic cancer	9.36e-06	5.79e-05	CcSEcCtD
Aprepitant—Anaemia—Doxorubicin—hematologic cancer	9.36e-06	5.79e-05	CcSEcCtD
Aprepitant—Thrombocytopenia—Methotrexate—hematologic cancer	9.35e-06	5.78e-05	CcSEcCtD
Aprepitant—Gastrointestinal pain—Prednisone—hematologic cancer	9.34e-06	5.77e-05	CcSEcCtD
Aprepitant—Nausea—Prednisolone—hematologic cancer	9.34e-06	5.77e-05	CcSEcCtD
Aprepitant—Chest pain—Epirubicin—hematologic cancer	9.32e-06	5.76e-05	CcSEcCtD
Aprepitant—Myalgia—Epirubicin—hematologic cancer	9.32e-06	5.76e-05	CcSEcCtD
Aprepitant—Arthralgia—Epirubicin—hematologic cancer	9.32e-06	5.76e-05	CcSEcCtD
Aprepitant—Anxiety—Epirubicin—hematologic cancer	9.29e-06	5.74e-05	CcSEcCtD
Aprepitant—Pruritus—Dexamethasone—hematologic cancer	9.28e-06	5.73e-05	CcSEcCtD
Aprepitant—Pruritus—Betamethasone—hematologic cancer	9.28e-06	5.73e-05	CcSEcCtD
Aprepitant—Skin disorder—Methotrexate—hematologic cancer	9.27e-06	5.73e-05	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	9.26e-06	5.72e-05	CcSEcCtD
Aprepitant—Hyperhidrosis—Methotrexate—hematologic cancer	9.23e-06	5.7e-05	CcSEcCtD
Aprepitant—Discomfort—Epirubicin—hematologic cancer	9.21e-06	5.69e-05	CcSEcCtD
Aprepitant—Vomiting—Triamcinolone—hematologic cancer	9.19e-06	5.68e-05	CcSEcCtD
Aprepitant—Malaise—Doxorubicin—hematologic cancer	9.14e-06	5.64e-05	CcSEcCtD
Aprepitant—Rash—Triamcinolone—hematologic cancer	9.12e-06	5.63e-05	CcSEcCtD
Aprepitant—Dry mouth—Epirubicin—hematologic cancer	9.12e-06	5.63e-05	CcSEcCtD
Aprepitant—Dermatitis—Triamcinolone—hematologic cancer	9.11e-06	5.63e-05	CcSEcCtD
Aprepitant—Anorexia—Methotrexate—hematologic cancer	9.1e-06	5.62e-05	CcSEcCtD
Aprepitant—Syncope—Doxorubicin—hematologic cancer	9.08e-06	5.61e-05	CcSEcCtD
Aprepitant—Urticaria—Prednisone—hematologic cancer	9.08e-06	5.61e-05	CcSEcCtD
Aprepitant—Headache—Triamcinolone—hematologic cancer	9.06e-06	5.6e-05	CcSEcCtD
Aprepitant—Body temperature increased—Prednisone—hematologic cancer	9.03e-06	5.58e-05	CcSEcCtD
Aprepitant—Abdominal pain—Prednisone—hematologic cancer	9.03e-06	5.58e-05	CcSEcCtD
Aprepitant—Confusional state—Epirubicin—hematologic cancer	9.01e-06	5.57e-05	CcSEcCtD
Aprepitant—Diarrhoea—Betamethasone—hematologic cancer	8.98e-06	5.55e-05	CcSEcCtD
Aprepitant—Diarrhoea—Dexamethasone—hematologic cancer	8.98e-06	5.55e-05	CcSEcCtD
Aprepitant—Palpitations—Doxorubicin—hematologic cancer	8.95e-06	5.53e-05	CcSEcCtD
Aprepitant—Anaphylactic shock—Epirubicin—hematologic cancer	8.94e-06	5.52e-05	CcSEcCtD
Aprepitant—Oedema—Epirubicin—hematologic cancer	8.94e-06	5.52e-05	CcSEcCtD
Aprepitant—Hypotension—Methotrexate—hematologic cancer	8.92e-06	5.51e-05	CcSEcCtD
Aprepitant—Loss of consciousness—Doxorubicin—hematologic cancer	8.9e-06	5.5e-05	CcSEcCtD
Aprepitant—Infection—Epirubicin—hematologic cancer	8.88e-06	5.48e-05	CcSEcCtD
Aprepitant—Cough—Doxorubicin—hematologic cancer	8.84e-06	5.46e-05	CcSEcCtD
Aprepitant—Shock—Epirubicin—hematologic cancer	8.79e-06	5.43e-05	CcSEcCtD
Aprepitant—Convulsion—Doxorubicin—hematologic cancer	8.78e-06	5.42e-05	CcSEcCtD
Aprepitant—Nervous system disorder—Epirubicin—hematologic cancer	8.76e-06	5.41e-05	CcSEcCtD
Aprepitant—Thrombocytopenia—Epirubicin—hematologic cancer	8.75e-06	5.41e-05	CcSEcCtD
Aprepitant—Hypertension—Doxorubicin—hematologic cancer	8.75e-06	5.4e-05	CcSEcCtD
Aprepitant—Tachycardia—Epirubicin—hematologic cancer	8.72e-06	5.39e-05	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Methotrexate—hematologic cancer	8.7e-06	5.37e-05	CcSEcCtD
Aprepitant—Skin disorder—Epirubicin—hematologic cancer	8.68e-06	5.36e-05	CcSEcCtD
Aprepitant—Dizziness—Betamethasone—hematologic cancer	8.68e-06	5.36e-05	CcSEcCtD
Aprepitant—Dizziness—Dexamethasone—hematologic cancer	8.68e-06	5.36e-05	CcSEcCtD
Aprepitant—Hyperhidrosis—Epirubicin—hematologic cancer	8.64e-06	5.34e-05	CcSEcCtD
Aprepitant—Insomnia—Methotrexate—hematologic cancer	8.64e-06	5.34e-05	CcSEcCtD
Aprepitant—Chest pain—Doxorubicin—hematologic cancer	8.62e-06	5.33e-05	CcSEcCtD
Aprepitant—Myalgia—Doxorubicin—hematologic cancer	8.62e-06	5.33e-05	CcSEcCtD
Aprepitant—Arthralgia—Doxorubicin—hematologic cancer	8.62e-06	5.33e-05	CcSEcCtD
Aprepitant—Anxiety—Doxorubicin—hematologic cancer	8.59e-06	5.31e-05	CcSEcCtD
Aprepitant—Nausea—Triamcinolone—hematologic cancer	8.59e-06	5.31e-05	CcSEcCtD
Aprepitant—Paraesthesia—Methotrexate—hematologic cancer	8.57e-06	5.3e-05	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	8.57e-06	5.29e-05	CcSEcCtD
Aprepitant—Discomfort—Doxorubicin—hematologic cancer	8.52e-06	5.26e-05	CcSEcCtD
Aprepitant—Anorexia—Epirubicin—hematologic cancer	8.52e-06	5.26e-05	CcSEcCtD
Aprepitant—Dyspnoea—Methotrexate—hematologic cancer	8.51e-06	5.26e-05	CcSEcCtD
Aprepitant—Somnolence—Methotrexate—hematologic cancer	8.49e-06	5.24e-05	CcSEcCtD
Aprepitant—Dry mouth—Doxorubicin—hematologic cancer	8.44e-06	5.21e-05	CcSEcCtD
Aprepitant—Hypersensitivity—Prednisone—hematologic cancer	8.42e-06	5.2e-05	CcSEcCtD
Aprepitant—Dyspepsia—Methotrexate—hematologic cancer	8.41e-06	5.19e-05	CcSEcCtD
Aprepitant—Hypotension—Epirubicin—hematologic cancer	8.35e-06	5.16e-05	CcSEcCtD
Aprepitant—Vomiting—Dexamethasone—hematologic cancer	8.34e-06	5.15e-05	CcSEcCtD
Aprepitant—Vomiting—Betamethasone—hematologic cancer	8.34e-06	5.15e-05	CcSEcCtD
Aprepitant—Confusional state—Doxorubicin—hematologic cancer	8.34e-06	5.15e-05	CcSEcCtD
Aprepitant—Decreased appetite—Methotrexate—hematologic cancer	8.3e-06	5.13e-05	CcSEcCtD
Aprepitant—Rash—Betamethasone—hematologic cancer	8.27e-06	5.11e-05	CcSEcCtD
Aprepitant—Rash—Dexamethasone—hematologic cancer	8.27e-06	5.11e-05	CcSEcCtD
Aprepitant—Oedema—Doxorubicin—hematologic cancer	8.27e-06	5.11e-05	CcSEcCtD
Aprepitant—Anaphylactic shock—Doxorubicin—hematologic cancer	8.27e-06	5.11e-05	CcSEcCtD
Aprepitant—Dermatitis—Dexamethasone—hematologic cancer	8.26e-06	5.11e-05	CcSEcCtD
Aprepitant—Dermatitis—Betamethasone—hematologic cancer	8.26e-06	5.11e-05	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Methotrexate—hematologic cancer	8.24e-06	5.09e-05	CcSEcCtD
Aprepitant—Fatigue—Methotrexate—hematologic cancer	8.23e-06	5.09e-05	CcSEcCtD
Aprepitant—Headache—Dexamethasone—hematologic cancer	8.22e-06	5.08e-05	CcSEcCtD
Aprepitant—Headache—Betamethasone—hematologic cancer	8.22e-06	5.08e-05	CcSEcCtD
Aprepitant—Infection—Doxorubicin—hematologic cancer	8.21e-06	5.07e-05	CcSEcCtD
Aprepitant—Asthenia—Prednisone—hematologic cancer	8.2e-06	5.06e-05	CcSEcCtD
Aprepitant—Pain—Methotrexate—hematologic cancer	8.17e-06	5.04e-05	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Epirubicin—hematologic cancer	8.14e-06	5.03e-05	CcSEcCtD
Aprepitant—Shock—Doxorubicin—hematologic cancer	8.13e-06	5.03e-05	CcSEcCtD
Aprepitant—Nervous system disorder—Doxorubicin—hematologic cancer	8.11e-06	5.01e-05	CcSEcCtD
Aprepitant—Thrombocytopenia—Doxorubicin—hematologic cancer	8.1e-06	5e-05	CcSEcCtD
Aprepitant—Pruritus—Prednisone—hematologic cancer	8.08e-06	4.99e-05	CcSEcCtD
Aprepitant—Insomnia—Epirubicin—hematologic cancer	8.08e-06	4.99e-05	CcSEcCtD
Aprepitant—Tachycardia—Doxorubicin—hematologic cancer	8.07e-06	4.99e-05	CcSEcCtD
Aprepitant—Skin disorder—Doxorubicin—hematologic cancer	8.03e-06	4.96e-05	CcSEcCtD
Aprepitant—Paraesthesia—Epirubicin—hematologic cancer	8.02e-06	4.96e-05	CcSEcCtD
Aprepitant—Hyperhidrosis—Doxorubicin—hematologic cancer	7.99e-06	4.94e-05	CcSEcCtD
Aprepitant—Dyspnoea—Epirubicin—hematologic cancer	7.97e-06	4.92e-05	CcSEcCtD
Aprepitant—Somnolence—Epirubicin—hematologic cancer	7.94e-06	4.91e-05	CcSEcCtD
Aprepitant—Anorexia—Doxorubicin—hematologic cancer	7.88e-06	4.87e-05	CcSEcCtD
Aprepitant—Feeling abnormal—Methotrexate—hematologic cancer	7.87e-06	4.86e-05	CcSEcCtD
Aprepitant—Dyspepsia—Epirubicin—hematologic cancer	7.87e-06	4.86e-05	CcSEcCtD
Aprepitant—Diarrhoea—Prednisone—hematologic cancer	7.82e-06	4.83e-05	CcSEcCtD
Aprepitant—Gastrointestinal pain—Methotrexate—hematologic cancer	7.81e-06	4.82e-05	CcSEcCtD
Aprepitant—Nausea—Betamethasone—hematologic cancer	7.79e-06	4.81e-05	CcSEcCtD
Aprepitant—Nausea—Dexamethasone—hematologic cancer	7.79e-06	4.81e-05	CcSEcCtD
Aprepitant—Decreased appetite—Epirubicin—hematologic cancer	7.77e-06	4.8e-05	CcSEcCtD
Aprepitant—Hypotension—Doxorubicin—hematologic cancer	7.73e-06	4.77e-05	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Epirubicin—hematologic cancer	7.71e-06	4.77e-05	CcSEcCtD
Aprepitant—Fatigue—Epirubicin—hematologic cancer	7.7e-06	4.76e-05	CcSEcCtD
Aprepitant—Constipation—Epirubicin—hematologic cancer	7.64e-06	4.72e-05	CcSEcCtD
Aprepitant—Pain—Epirubicin—hematologic cancer	7.64e-06	4.72e-05	CcSEcCtD
Aprepitant—Urticaria—Methotrexate—hematologic cancer	7.59e-06	4.69e-05	CcSEcCtD
Aprepitant—Dizziness—Prednisone—hematologic cancer	7.56e-06	4.67e-05	CcSEcCtD
Aprepitant—Abdominal pain—Methotrexate—hematologic cancer	7.55e-06	4.66e-05	CcSEcCtD
Aprepitant—Body temperature increased—Methotrexate—hematologic cancer	7.55e-06	4.66e-05	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	7.53e-06	4.65e-05	CcSEcCtD
Aprepitant—Insomnia—Doxorubicin—hematologic cancer	7.48e-06	4.62e-05	CcSEcCtD
Aprepitant—Paraesthesia—Doxorubicin—hematologic cancer	7.42e-06	4.59e-05	CcSEcCtD
Aprepitant—Dyspnoea—Doxorubicin—hematologic cancer	7.37e-06	4.55e-05	CcSEcCtD
Aprepitant—Feeling abnormal—Epirubicin—hematologic cancer	7.36e-06	4.55e-05	CcSEcCtD
Aprepitant—Somnolence—Doxorubicin—hematologic cancer	7.35e-06	4.54e-05	CcSEcCtD
Aprepitant—Gastrointestinal pain—Epirubicin—hematologic cancer	7.31e-06	4.51e-05	CcSEcCtD
Aprepitant—Dyspepsia—Doxorubicin—hematologic cancer	7.28e-06	4.5e-05	CcSEcCtD
Aprepitant—Vomiting—Prednisone—hematologic cancer	7.26e-06	4.49e-05	CcSEcCtD
Aprepitant—Rash—Prednisone—hematologic cancer	7.2e-06	4.45e-05	CcSEcCtD
Aprepitant—Dermatitis—Prednisone—hematologic cancer	7.2e-06	4.45e-05	CcSEcCtD
Aprepitant—Decreased appetite—Doxorubicin—hematologic cancer	7.19e-06	4.44e-05	CcSEcCtD
Aprepitant—Headache—Prednisone—hematologic cancer	7.16e-06	4.42e-05	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Doxorubicin—hematologic cancer	7.14e-06	4.41e-05	CcSEcCtD
Aprepitant—Fatigue—Doxorubicin—hematologic cancer	7.13e-06	4.4e-05	CcSEcCtD
Aprepitant—Urticaria—Epirubicin—hematologic cancer	7.1e-06	4.39e-05	CcSEcCtD
Aprepitant—Constipation—Doxorubicin—hematologic cancer	7.07e-06	4.37e-05	CcSEcCtD
Aprepitant—Pain—Doxorubicin—hematologic cancer	7.07e-06	4.37e-05	CcSEcCtD
Aprepitant—Abdominal pain—Epirubicin—hematologic cancer	7.06e-06	4.36e-05	CcSEcCtD
Aprepitant—Body temperature increased—Epirubicin—hematologic cancer	7.06e-06	4.36e-05	CcSEcCtD
Aprepitant—Hypersensitivity—Methotrexate—hematologic cancer	7.03e-06	4.35e-05	CcSEcCtD
Aprepitant—Asthenia—Methotrexate—hematologic cancer	6.85e-06	4.23e-05	CcSEcCtD
Aprepitant—Feeling abnormal—Doxorubicin—hematologic cancer	6.81e-06	4.21e-05	CcSEcCtD
Aprepitant—Nausea—Prednisone—hematologic cancer	6.79e-06	4.19e-05	CcSEcCtD
Aprepitant—Gastrointestinal pain—Doxorubicin—hematologic cancer	6.76e-06	4.18e-05	CcSEcCtD
Aprepitant—Pruritus—Methotrexate—hematologic cancer	6.76e-06	4.17e-05	CcSEcCtD
Aprepitant—Hypersensitivity—Epirubicin—hematologic cancer	6.58e-06	4.07e-05	CcSEcCtD
Aprepitant—Urticaria—Doxorubicin—hematologic cancer	6.57e-06	4.06e-05	CcSEcCtD
Aprepitant—Body temperature increased—Doxorubicin—hematologic cancer	6.54e-06	4.04e-05	CcSEcCtD
Aprepitant—Abdominal pain—Doxorubicin—hematologic cancer	6.54e-06	4.04e-05	CcSEcCtD
Aprepitant—Diarrhoea—Methotrexate—hematologic cancer	6.53e-06	4.04e-05	CcSEcCtD
Aprepitant—Asthenia—Epirubicin—hematologic cancer	6.41e-06	3.96e-05	CcSEcCtD
Aprepitant—Pruritus—Epirubicin—hematologic cancer	6.32e-06	3.91e-05	CcSEcCtD
Aprepitant—Dizziness—Methotrexate—hematologic cancer	6.31e-06	3.9e-05	CcSEcCtD
Aprepitant—Diarrhoea—Epirubicin—hematologic cancer	6.11e-06	3.78e-05	CcSEcCtD
Aprepitant—Hypersensitivity—Doxorubicin—hematologic cancer	6.09e-06	3.76e-05	CcSEcCtD
Aprepitant—Vomiting—Methotrexate—hematologic cancer	6.07e-06	3.75e-05	CcSEcCtD
Aprepitant—Rash—Methotrexate—hematologic cancer	6.02e-06	3.72e-05	CcSEcCtD
Aprepitant—Dermatitis—Methotrexate—hematologic cancer	6.01e-06	3.72e-05	CcSEcCtD
Aprepitant—Headache—Methotrexate—hematologic cancer	5.98e-06	3.7e-05	CcSEcCtD
Aprepitant—Asthenia—Doxorubicin—hematologic cancer	5.93e-06	3.67e-05	CcSEcCtD
Aprepitant—Dizziness—Epirubicin—hematologic cancer	5.91e-06	3.65e-05	CcSEcCtD
Aprepitant—Pruritus—Doxorubicin—hematologic cancer	5.85e-06	3.61e-05	CcSEcCtD
Aprepitant—Vomiting—Epirubicin—hematologic cancer	5.68e-06	3.51e-05	CcSEcCtD
Aprepitant—Nausea—Methotrexate—hematologic cancer	5.67e-06	3.5e-05	CcSEcCtD
Aprepitant—Diarrhoea—Doxorubicin—hematologic cancer	5.66e-06	3.5e-05	CcSEcCtD
Aprepitant—Rash—Epirubicin—hematologic cancer	5.63e-06	3.48e-05	CcSEcCtD
Aprepitant—Dermatitis—Epirubicin—hematologic cancer	5.63e-06	3.48e-05	CcSEcCtD
Aprepitant—Headache—Epirubicin—hematologic cancer	5.6e-06	3.46e-05	CcSEcCtD
Aprepitant—Dizziness—Doxorubicin—hematologic cancer	5.47e-06	3.38e-05	CcSEcCtD
Aprepitant—Nausea—Epirubicin—hematologic cancer	5.31e-06	3.28e-05	CcSEcCtD
Aprepitant—Vomiting—Doxorubicin—hematologic cancer	5.26e-06	3.25e-05	CcSEcCtD
Aprepitant—Rash—Doxorubicin—hematologic cancer	5.21e-06	3.22e-05	CcSEcCtD
Aprepitant—Dermatitis—Doxorubicin—hematologic cancer	5.21e-06	3.22e-05	CcSEcCtD
Aprepitant—Headache—Doxorubicin—hematologic cancer	5.18e-06	3.2e-05	CcSEcCtD
Aprepitant—Nausea—Doxorubicin—hematologic cancer	4.91e-06	3.03e-05	CcSEcCtD
Aprepitant—CYP3A5—Metabolism—GSTT1—hematologic cancer	4.55e-06	0.000106	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ABCC3—hematologic cancer	4.54e-06	0.000105	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—TXN—hematologic cancer	4.54e-06	0.000105	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTO1—hematologic cancer	4.54e-06	0.000105	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MAPK8—hematologic cancer	4.49e-06	0.000104	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—AKT1—hematologic cancer	4.48e-06	0.000104	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—FHL2—hematologic cancer	4.47e-06	0.000104	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CA9—hematologic cancer	4.45e-06	0.000103	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ACP5—hematologic cancer	4.45e-06	0.000103	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—SDC1—hematologic cancer	4.45e-06	0.000103	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SPHK1—hematologic cancer	4.44e-06	0.000103	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NCOR2—hematologic cancer	4.39e-06	0.000102	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AGRN—hematologic cancer	4.39e-06	0.000102	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PC—hematologic cancer	4.39e-06	0.000102	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EP300—hematologic cancer	4.38e-06	0.000102	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GSTP1—hematologic cancer	4.36e-06	0.000101	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—UGT1A1—hematologic cancer	4.27e-06	9.92e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SRC—hematologic cancer	4.26e-06	9.9e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GBA—hematologic cancer	4.24e-06	9.84e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SLC35B2—hematologic cancer	4.24e-06	9.84e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—IDH1—hematologic cancer	4.19e-06	9.73e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—IDH2—hematologic cancer	4.16e-06	9.67e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—HMMR—hematologic cancer	4.16e-06	9.67e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SLC22A1—hematologic cancer	4.15e-06	9.65e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CRABP1—hematologic cancer	4.15e-06	9.65e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—VEGFA—hematologic cancer	4.15e-06	9.64e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ABCC3—hematologic cancer	4.14e-06	9.62e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—TXN—hematologic cancer	4.14e-06	9.62e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTO1—hematologic cancer	4.14e-06	9.62e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ABCB1—hematologic cancer	4.13e-06	9.6e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—STAT3—hematologic cancer	4.11e-06	9.55e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NRAS—hematologic cancer	4.1e-06	9.52e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SPHK1—hematologic cancer	4.05e-06	9.41e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ALOX5—hematologic cancer	4.05e-06	9.4e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—NCOR1—hematologic cancer	4.01e-06	9.32e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GSTM1—hematologic cancer	4.01e-06	9.32e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MAPK3—hematologic cancer	3.92e-06	9.12e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	3.92e-06	9.12e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NUP98—hematologic cancer	3.92e-06	9.11e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ARNTL—hematologic cancer	3.91e-06	9.09e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—UGT1A1—hematologic cancer	3.89e-06	9.04e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—MTAP—hematologic cancer	3.87e-06	9e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MYC—hematologic cancer	3.82e-06	8.87e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TGFB1—hematologic cancer	3.81e-06	8.85e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CA9—hematologic cancer	3.8e-06	8.84e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ACP5—hematologic cancer	3.8e-06	8.84e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ADCY7—hematologic cancer	3.8e-06	8.84e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NCOA3—hematologic cancer	3.8e-06	8.84e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SLC22A1—hematologic cancer	3.78e-06	8.8e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CRABP1—hematologic cancer	3.78e-06	8.8e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CD44—hematologic cancer	3.78e-06	8.79e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NQO1—hematologic cancer	3.78e-06	8.79e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NUP214—hematologic cancer	3.78e-06	8.78e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NCOR2—hematologic cancer	3.75e-06	8.73e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	3.74e-06	8.69e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ABCG2—hematologic cancer	3.7e-06	8.6e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—MTR—hematologic cancer	3.7e-06	8.6e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ALOX5—hematologic cancer	3.69e-06	8.57e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ENO2—hematologic cancer	3.63e-06	8.43e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYCS—hematologic cancer	3.58e-06	8.32e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—IDH1—hematologic cancer	3.58e-06	8.31e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NUP98—hematologic cancer	3.57e-06	8.3e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—HSP90AA1—hematologic cancer	3.56e-06	8.27e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—MTHFR—hematologic cancer	3.54e-06	8.24e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—TXN—hematologic cancer	3.54e-06	8.22e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ABCC3—hematologic cancer	3.54e-06	8.22e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTO1—hematologic cancer	3.54e-06	8.22e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—KRAS—hematologic cancer	3.53e-06	8.2e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTT1—hematologic cancer	3.52e-06	8.18e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ADCY7—hematologic cancer	3.47e-06	8.06e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NCOA3—hematologic cancer	3.47e-06	8.06e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.47e-06	8.05e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SPHK1—hematologic cancer	3.46e-06	8.04e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—FHL2—hematologic cancer	3.45e-06	8.02e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NUP214—hematologic cancer	3.44e-06	8e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SDC1—hematologic cancer	3.44e-06	7.99e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	3.41e-06	7.92e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AGRN—hematologic cancer	3.39e-06	7.87e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—MTR—hematologic cancer	3.37e-06	7.84e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ABCG2—hematologic cancer	3.37e-06	7.84e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—UGT1A1—hematologic cancer	3.32e-06	7.73e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ENO2—hematologic cancer	3.31e-06	7.69e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.29e-06	7.64e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.24e-06	7.54e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PIK3CA—hematologic cancer	3.24e-06	7.53e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CRABP1—hematologic cancer	3.23e-06	7.52e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SLC22A1—hematologic cancer	3.23e-06	7.52e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—IDH2—hematologic cancer	3.21e-06	7.46e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—HMMR—hematologic cancer	3.21e-06	7.46e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTT1—hematologic cancer	3.21e-06	7.46e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.16e-06	7.34e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTP1—hematologic cancer	3.16e-06	7.33e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ALOX5—hematologic cancer	3.15e-06	7.33e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SDC1—hematologic cancer	3.14e-06	7.29e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TP53—hematologic cancer	3.13e-06	7.29e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.1e-06	7.21e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NUP98—hematologic cancer	3.05e-06	7.1e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ARNTL—hematologic cancer	3.02e-06	7.01e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HRAS—hematologic cancer	3e-06	6.97e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3e-06	6.96e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ABCB1—hematologic cancer	2.99e-06	6.94e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CG—hematologic cancer	2.98e-06	6.92e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NCOA3—hematologic cancer	2.96e-06	6.89e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ADCY7—hematologic cancer	2.96e-06	6.89e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	2.96e-06	6.87e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NUP214—hematologic cancer	2.94e-06	6.84e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ACP5—hematologic cancer	2.94e-06	6.82e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CA9—hematologic cancer	2.94e-06	6.82e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NQO1—hematologic cancer	2.92e-06	6.8e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CD44—hematologic cancer	2.92e-06	6.8e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	2.91e-06	6.77e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTM1—hematologic cancer	2.9e-06	6.74e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NCOR1—hematologic cancer	2.9e-06	6.74e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NCOR2—hematologic cancer	2.9e-06	6.73e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—MTR—hematologic cancer	2.88e-06	6.7e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ABCG2—hematologic cancer	2.88e-06	6.7e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL6—hematologic cancer	2.87e-06	6.67e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.86e-06	6.66e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.83e-06	6.58e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ENO2—hematologic cancer	2.83e-06	6.57e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYCS—hematologic cancer	2.77e-06	6.43e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CREBBP—hematologic cancer	2.76e-06	6.42e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—IDH1—hematologic cancer	2.76e-06	6.42e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	2.75e-06	6.39e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTT1—hematologic cancer	2.74e-06	6.37e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ABCC3—hematologic cancer	2.73e-06	6.34e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—TXN—hematologic cancer	2.73e-06	6.34e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTO1—hematologic cancer	2.73e-06	6.34e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	2.7e-06	6.28e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SDC1—hematologic cancer	2.68e-06	6.23e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SPHK1—hematologic cancer	2.67e-06	6.21e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CD44—hematologic cancer	2.67e-06	6.2e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NQO1—hematologic cancer	2.67e-06	6.2e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AKT1—hematologic cancer	2.65e-06	6.15e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CD—hematologic cancer	2.62e-06	6.09e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.61e-06	6.07e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ALB—hematologic cancer	2.58e-06	6.01e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—UGT1A1—hematologic cancer	2.57e-06	5.96e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—MTHFR—hematologic cancer	2.56e-06	5.96e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	2.56e-06	5.95e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	2.53e-06	5.87e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYCS—hematologic cancer	2.52e-06	5.86e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	2.51e-06	5.83e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SLC22A1—hematologic cancer	2.5e-06	5.8e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CRABP1—hematologic cancer	2.5e-06	5.8e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.47e-06	5.75e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3R1—hematologic cancer	2.47e-06	5.75e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTP1—hematologic cancer	2.44e-06	5.67e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ALOX5—hematologic cancer	2.43e-06	5.65e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.42e-06	5.62e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.36e-06	5.49e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NUP98—hematologic cancer	2.36e-06	5.48e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ABCB1—hematologic cancer	2.31e-06	5.37e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.29e-06	5.32e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.29e-06	5.32e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CB—hematologic cancer	2.28e-06	5.3e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CD44—hematologic cancer	2.28e-06	5.3e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NQO1—hematologic cancer	2.28e-06	5.3e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NUP214—hematologic cancer	2.27e-06	5.28e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.26e-06	5.24e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTM1—hematologic cancer	2.24e-06	5.21e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NCOR1—hematologic cancer	2.24e-06	5.21e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.23e-06	5.19e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—MTR—hematologic cancer	2.22e-06	5.17e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.22e-06	5.17e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTP1—hematologic cancer	2.22e-06	5.17e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ENO2—hematologic cancer	2.18e-06	5.07e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYCS—hematologic cancer	2.16e-06	5.01e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CG—hematologic cancer	2.15e-06	5e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.15e-06	5e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	2.14e-06	4.98e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.12e-06	4.92e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ABCB1—hematologic cancer	2.11e-06	4.89e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SDC1—hematologic cancer	2.07e-06	4.81e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTM1—hematologic cancer	2.04e-06	4.75e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NCOR1—hematologic cancer	2.04e-06	4.75e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CREBBP—hematologic cancer	2e-06	4.64e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—MTHFR—hematologic cancer	1.98e-06	4.6e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTEN—hematologic cancer	1.97e-06	4.58e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.93e-06	4.48e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTP1—hematologic cancer	1.9e-06	4.42e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CD—hematologic cancer	1.89e-06	4.4e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—EP300—hematologic cancer	1.88e-06	4.37e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ALB—hematologic cancer	1.87e-06	4.34e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.84e-06	4.27e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.81e-06	4.2e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ABCB1—hematologic cancer	1.8e-06	4.18e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3R1—hematologic cancer	1.79e-06	4.15e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NQO1—hematologic cancer	1.76e-06	4.09e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CD44—hematologic cancer	1.76e-06	4.09e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTM1—hematologic cancer	1.75e-06	4.06e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NCOR1—hematologic cancer	1.75e-06	4.06e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.75e-06	4.06e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.66e-06	3.87e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYCS—hematologic cancer	1.66e-06	3.87e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.65e-06	3.84e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CB—hematologic cancer	1.65e-06	3.83e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.59e-06	3.7e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.54e-06	3.59e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.54e-06	3.59e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.52e-06	3.53e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.47e-06	3.41e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CD—hematologic cancer	1.46e-06	3.4e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ALB—hematologic cancer	1.44e-06	3.36e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTEN—hematologic cancer	1.43e-06	3.31e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.41e-06	3.27e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CA—hematologic cancer	1.39e-06	3.23e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.39e-06	3.23e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.38e-06	3.21e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.36e-06	3.16e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—EP300—hematologic cancer	1.36e-06	3.16e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.35e-06	3.13e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.35e-06	3.13e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.33e-06	3.1e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ALB—hematologic cancer	1.32e-06	3.06e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.3e-06	3.01e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.28e-06	2.96e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.26e-06	2.93e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.2e-06	2.79e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.19e-06	2.77e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.16e-06	2.7e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.14e-06	2.65e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—AKT1—hematologic cancer	1.14e-06	2.64e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ALB—hematologic cancer	1.13e-06	2.62e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTEN—hematologic cancer	1.1e-06	2.56e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.08e-06	2.5e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—EP300—hematologic cancer	1.05e-06	2.44e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CA—hematologic cancer	1.01e-06	2.34e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTEN—hematologic cancer	1e-06	2.34e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1e-06	2.33e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CB—hematologic cancer	9.94e-07	2.31e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—EP300—hematologic cancer	9.58e-07	2.23e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CREBBP—hematologic cancer	9.28e-07	2.16e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CD—hematologic cancer	8.8e-07	2.05e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ALB—hematologic cancer	8.69e-07	2.02e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTEN—hematologic cancer	8.59e-07	2e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3R1—hematologic cancer	8.31e-07	1.93e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—AKT1—hematologic cancer	8.22e-07	1.91e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—EP300—hematologic cancer	8.19e-07	1.9e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CA—hematologic cancer	7.77e-07	1.81e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CB—hematologic cancer	7.67e-07	1.78e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CA—hematologic cancer	7.09e-07	1.65e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTEN—hematologic cancer	6.63e-07	1.54e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—AKT1—hematologic cancer	6.35e-07	1.48e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—EP300—hematologic cancer	6.32e-07	1.47e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CA—hematologic cancer	6.06e-07	1.41e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—AKT1—hematologic cancer	5.79e-07	1.35e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AKT1—hematologic cancer	4.95e-07	1.15e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CA—hematologic cancer	4.68e-07	1.09e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AKT1—hematologic cancer	3.82e-07	8.88e-06	CbGpPWpGaD
